Glucagon-like peptide-1/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: A randomized trial

2023-03-27T12:42:07+02:00

Contributo: Paola Fierabracci Glucagon-like peptide-1/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: A randomized trial Karen D. Corbin, Elvis A. Carnero, Timothy D. Allerton, Joachim Tillner, Christopher P.

Glucagon-like peptide-1/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: A randomized trial2023-03-27T12:42:07+02:00

The Effects of Eight Weeks’ Very Low-Calorie Ketogenic Diet (VLCKD) on Liver Health in Subjects Affected by Overweight and Obesity

2023-03-27T12:38:51+02:00

Contributo: Barrea The Effects of Eight Weeks' Very Low-Calorie Ketogenic Diet (VLCKD) on Liver Health in Subjects Affected by Overweight and Obesity Effetto di otto settimane di dieta chetogenica a bassissimo contenuto

The Effects of Eight Weeks’ Very Low-Calorie Ketogenic Diet (VLCKD) on Liver Health in Subjects Affected by Overweight and Obesity2023-03-27T12:38:51+02:00

Impatto del BMI e delle comorbidità sull’efficacia della somministrazione di semaglutide una volta alla settimana: analisi post-hoc del trial randomizzato STEP-1

2023-03-27T12:30:03+02:00

Contributo: Simona Bo Impatto del BMI e delle comorbidità sull’efficacia della somministrazione di semaglutide una volta alla settimana: analisi post-hoc del trial randomizzato STEP-1 Impact of BMI and comorbidities on efficacy of

Impatto del BMI e delle comorbidità sull’efficacia della somministrazione di semaglutide una volta alla settimana: analisi post-hoc del trial randomizzato STEP-12023-03-27T12:30:03+02:00

Calorie Restriction with or without Time-Restricted Eating in Weight Loss Restrizione calorica con o senza mangiare in un arco di tempo ristretto nella perdita di peso

2023-01-23T23:21:34+01:00

Contributo di Luisa Lampignano Calorie Restriction with or without Time-Restricted Eating in Weight Loss Restrizione calorica con o senza mangiare in un arco di tempo ristretto nella perdita di peso Background

Calorie Restriction with or without Time-Restricted Eating in Weight Loss Restrizione calorica con o senza mangiare in un arco di tempo ristretto nella perdita di peso2023-01-23T23:21:34+01:00

Nuove terapie per l’obesità

2022-12-15T16:31:20+01:00

Contributo: Melania Manco Papamargaritis D, le Roux CW, Holst JJ, Davies MJ. New therapies for obesity. Cardiovasc Res. 2022 Nov 30:cvac176. doi: 10.1093/cvr/cvac176. Epub ahead of print. Nuove terapie per l’obesità

Nuove terapie per l’obesità2022-12-15T16:31:20+01:00

LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.

2022-12-15T16:23:50+01:00

Contributo: Camastra LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Shweta Urva, Tamer Coskun,

LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.2022-12-15T16:23:50+01:00

Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial

2022-11-25T17:49:36+01:00

Contributo: Bianciardi Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial Naltrexone-Bupropione e terapia comportamentale, da soli e combinati, per il disturbo da alimentazione incontrollata: trial

Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial2022-11-25T17:49:36+01:00

LOGIN SOCI

Torna in cima